Clinical trials: Controlled Diabetes
Type 2 Diabetes
A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
This study is a Phase 2, randomized, double-blind, placebo-controlled, single-center study in adult patients with type 2 diabetes. It will evaluate the safety and tolerability of oral GLY-200.
- Trial name
- NCT05478525
- Testing
- GLY-200
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Glyscend, Inc.
Diabetes Mellitus, Type 2
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg…
- Trial name
- NCT00641043
- Testing
- Linagliptin + pioglitazone (30 mg)
- Where
- 43 sites in Austria, Greece and 5 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
This is a double-blind, randomized, placebo-controlled, multi-center study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM.
- Trial name
- NCT04618744
- Testing
- ORMD-0801 (Insulin) capsule 8 mg BD
- Where
- 3 sites in United States, Israel
- Volunteers
- 32 people
- Sponsor
- Oramed, Ltd.
Type 1 Diabetes
The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes
The purpose of this study is to measure the metabolic phenotype of a range of body weights in individuals with and without type 1 diabetes.
- Trial name
- ACME (NCT03379792)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Diabetes Mellitus, Type 2, Coronary Artery Disease
SMBG Protocols Predicting Glucose Levels in Senior Diabetes Mellitus With CAD
Self-monitoring of blood glucose (SMBG) is a common way to assess glycemic control in diabetes management. Multiple times of blood glucose measurements by fingerstick in the same day are of tough challenge to it.
- Trial name
- NCT01954771
- Testing
- SMBG, CGMS
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Beijing Anzhen Hospital
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Type 1 Diabetes Mellitus
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin.
- Trial name
- DIA-AID2 (NCT01103284)
- Testing
- DiaPep277
- Where
- 75 sites in United States, Austria and 12 more
- Volunteers
- 475 people
- Sponsor
- Andromeda Biotech Ltd.
Type 1 Diabetes Mellitus
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus
This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years old) and teens/adults (ages 12-35 years old) with…
- Trial name
- NCT02093221
- Testing
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI
- Where
- 36 sites in United States
- Volunteers
- 76 people
- Sponsor
- Grifols Therapeutics LLC
Diabetes Mellitus, Type 2
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
The aim of this study is to investigate the impact of the combination therapy of linagliptin and metformin at submaximal doses in reduction of Glycosylated haemoglobin (HbA1c) and metformin pre-specified gastro-intestinal (GI)…
- Trial name
- NCT01438814
- Testing
- metformin, linagliptin
- Where
- 90 sites in Bangladesh, Belgium and 12 more
- Volunteers
- 689 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin.
- Trial name
- NCT02489968
- Testing
- empagliflozin 10 mg + linagliptin 5 mg, empagliflozin 10 mg, empagliflozin 25 mg + linagliptin 5 mg
- Where
- 83 sites in Japan
- Volunteers
- 880 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
This is a Phase 2a, randomized, blinded, placebo-controlled study in up to 20 overweight or obese participants with type 2 diabetes mellitus.
- Trial name
- NCT03745937
- Testing
- MEDI0382
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- MedImmune LLC
Hypertension, Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.
- Conditions
- Hypertension, Stage 2 Hypertension, Diabetes
- Trial name
- VALENCIA (NCT01368536)
- Testing
- Valturna, Amlodipine, Chlorthalidone
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 975 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes, Type 2 Diabetes
ACCESS: AI for pediatriC diabetiC Eye examS Study
The purpose of this study is to determine if providing in clinic point-of-care autonomous AI diabetic retinopathy exams improves screening rates compared to standard of care referral to an eye care provider, in a randomized…
- Trial name
- ACCESS (NCT05131451)
- Testing
- Point of Care Autonomous AI diabetic retinopathy exam
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Johns Hopkins University
Type 2 Diabetes Mellitus
Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)
The purpose of this study is to evaluate the effect of SCH 497079 on metabolic parameters and to determine the influence of race/ethnic origin on therapeutic response.
- Trial name
- NCT00673465
- Testing
- SCH 497079, Metformin
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Diabetes Mellitus, Type II
Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control
This is a 24-week, prospective, multicenter, open-label, single-arm study to assess the effect of bisoprolol on glycemic level in Type 2 diabetes mellitus (T2DM) controlled subjects with hypertension.
- Trial name
- GIANT (NCT01066039)
- Testing
- Bisoprolol
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Type2 Diabetes, Cardiovascular Diseases
Peanuts and Glycemic Control
A two-period randomized crossover study will be conducted to determine the effect of peanuts on glycemic control, and elucidate the role of the microbiome in glucose regulation, in individuals with impaired fasting glucose.
- Trial name
- NCT03654651
- Testing
- Peanut, High carbohydrate snack
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Penn State University
Diabetes Mellitus, Type 2
A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
This will be a 2-week oral dose study of PF 04991532, performed in patients with type 2 diabetes. Safety, pharmacokinetics (how the drug is distributed in the body), and pharmacodynamics (how the drug works in the body) will be…
- Trial name
- NCT01469065
- Testing
- PF-04991532, PF-0499132
- Where
- 3 sites in United States, Japan
- Volunteers
- 82 people
- Sponsor
- Pfizer
Pre Diabetes
Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation
Researchers are trying to determine if an anti-diabetes medication, called Exenatide SR, is well tolerated in kidney transplant patients with elevated blood glucose levels, and if it's effective in preventing diabetes.
- Trial name
- NCT03961256
- Testing
- Exenatide SR
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.